Altre lingue Nektar Therapeutics

Azioni

NKTR

US6402681083

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 14/06/2024			Variaz. 5gg	Var. 1 gen.
1,17 ^USD	-6,40%		-7,14%	+107,08%

10/06	Transcript : Nektar Therapeutics Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 02:00 PM
09/05	Nektar Therapeutics ribadisce la guidance sugli utili per l'anno 2024	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024	12/06
Nektar Management to Present at Upcoming Investor Conferences	31/05
Nektar: Q1 Earnings Snapshot	09/05
Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q1 Revenue $21.6M, vs. Street Est of $15.3M	09/05
Nektar Therapeutics Reiterates Earnings Guidance for the Year 2024	09/05
Nektar Therapeutics Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Nektar Therapeutics Reports First Quarter 2024 Financial Results	09/05
Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets	03/05
Nektar Therapeutics : SCHEDULE 14A	26/04
Biolojic Design Announces Nektar Therapeutics Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases	24/04
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune and Inflammatory Disease Virtual Conference	25/03
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference	22/03
Nektar Therapeutics announced that it has received $30 million in funding from TCG Crossover Management, LLC	19/03
Nektar Therapeutics Begins Phase 2b Trial for Rezpegaldesleukin in Patients With Severe Alopecia Areata	05/03
Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata	05/03
Nektar Therapeutics Announces Initiation of Phase 2B Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata	05/03
Nektar: Q4 Earnings Snapshot	04/03
Nektar Therapeutics Reports Earnings Results for the Full Year Ended December 31, 2023	04/03
Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q4 Revenue $23.9M, vs. Street Est of $21.4M	04/03
Nektar Therapeutics Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	04/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Nektar Therapeutics

Azioni

NKTR

US6402681083

Altre lingue

Filtri